Prepare Yourself for Liftoff: Cullinan Therapeutics Inc (CGEM)

With 0.72 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.49 million shares. The 52-week range on CGEM shows that it touched its highest point at $30.19 and its lowest point at $7.90 during that stretch. It currently has a 1-year price target of $32.11. Beta for the stock currently stands at -0.10.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CGEM was up-trending over the past week, with a rise of 6.64%, but this was down by -15.08% over a month. Three-month performance dropped to -30.31% while six-month performance fell -51.78%. The stock lost -46.97% in the past year, while it has lost -28.82% so far this year. A look at the trailing 12-month EPS for CGEM yields -3.14 with Next year EPS estimates of -3.12. For the next quarter, that number is -0.82. This implies an EPS growth rate of -16.89% for this year and 4.13% for next year. EPS is expected to decline by -0.82% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -45.66%.

Float and Shares Shorts:

At present, 58.51 million CGEM shares are outstanding with a float of 35.47 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CGEM since 4 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.90291 being high and -$3.27655 being low. For CGEM, this leads to a yearly average estimate of -$2.98913. Based on analyst estimates, the high estimate for the next quarter is -$0.69 and the low estimate is -$0.94. The average estimate for the next quarter is thus -$0.84.